| BIOVICA INTL. SK-,07 |
| Schweden |
| Gesundheit |
| SE0008613731 / A2DPS4 |
| 9II (Frankfurt) |
| FRA:9II, ETR:9II, 9II:GR |
| - |
| https://biovica.com/ |
|
Biovica International AB, a key player in the biotechnology industry, specializes in the development and commercialization of diagnostic solutions that aim to enhance cancer treatment. The company's primary product, DiviTum, provides a revolutionary ..
>Volltext.. |
| 9.61 Mio. EUR |
| 1.74 Mio. EUR |
| 1.06 Mio. EUR |
| -6.2 Mio. EUR |
| -6.93 Mio. EUR |
| -0.04 EUR |
| 0.47 Mio. EUR |
| 8.54 Mio. EUR |
| -6.26 Mio. EUR |
| 4.96 |
| 45.03% |
| 26.77% |
| - |
| - |
| - |
| - |
| BIOVICA |
| 05.04.26 |
|